Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/j.1360-0443.2011.03771.x http://scihub22266oqcxt.onion/10.1111/j.1360-0443.2011.03771.x 22221594/?report=reader!3331916!22221594     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=22221594&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Addiction 2012 ; 107 (7): 1297-306 Nephropedia Template TP {{tp|p=22221594|t=2012. Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial |pdf=|usr=}}{{22221594}} gab.com Text Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial JO: Addiction http://www.kidney.de/pget.php?&tw=1&pmid=22221594 #FOAvip AIMS: Topiramate has shown efficacy at facilitating abstinence from alcohol and cocaine abuse. This double-blind, placebo-controlled out-patient trial tested topiramate for treating methamphetamine addiction. DESIGN: Participants (n = 140) were randomized to receive topiramate or placebo (13 weeks) in escalating doses from 25 mg/day [DOSAGE ERROR CORRECTED] to the target maintenance of 200 mg/day in weeks 6-12 (tapered in week 13). Medication was combined with weekly brief behavioral compliance enhancement treatment. SETTING: The trial was conducted at eight medical centers in the United States. PARTICIPANTS: One hundred and forty methamphetamine-dependent adults took part in the trial. MEASUREMENTS: The primary outcome was abstinence from methamphetamine during weeks 6-12. Secondary outcomes included use reduction versus baseline, as well as psychosocial variables. FINDINGS: In the intent-to-treat analysis, topiramate did not increase abstinence from methamphetamine during weeks 6-12. For secondary outcomes, topiramate reduced weekly median urine methamphetamine levels and observer-rated severity of dependence scores significantly. Subjects with negative urine before randomization (n = 26) had significantly greater abstinence on topiramate versus placebo during study weeks 6-12. Topiramate was safe and well tolerated. CONCLUSIONS: Topiramate does not appear to promote abstinence in methamphetamine users but can reduce the amount taken and reduce relapse rates in those who are already abstinent. Twit Text FOAVip Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial ????Addiction http://www.kidney.de/pget.php?&tw=1&pmid=22221594 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=22221594 #FOAvip English Wikipedia <ref>{{Cite pmid|22221594}}</ref> Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial #MMPMID22221594 Elkashef A; Kahn R; Yu E; Iturriaga E; Li SH; Anderson A; Chiang N; Ait-Daoud N; Weiss D; McSherry F; Serpi T; Rawson R; Hrymoc M; Weis D; McCann M; Pham T; Stock C; Dickinson R; Campbell J; Gorodetzky C; Haning W; Carlton B; Mawhinney J; Li MD; Johnson BA Addiction 2012[Jul]; 107 (7): 1297-306 PMID22221594show ga AIMS: Topiramate has shown efficacy at facilitating abstinence from alcohol and cocaine abuse. This double-blind, placebo-controlled out-patient trial tested topiramate for treating methamphetamine addiction. DESIGN: Participants (n = 140) were randomized to receive topiramate or placebo (13 weeks) in escalating doses from 25 mg/day [DOSAGE ERROR CORRECTED] to the target maintenance of 200 mg/day in weeks 6-12 (tapered in week 13). Medication was combined with weekly brief behavioral compliance enhancement treatment. SETTING: The trial was conducted at eight medical centers in the United States. PARTICIPANTS: One hundred and forty methamphetamine-dependent adults took part in the trial. MEASUREMENTS: The primary outcome was abstinence from methamphetamine during weeks 6-12. Secondary outcomes included use reduction versus baseline, as well as psychosocial variables. FINDINGS: In the intent-to-treat analysis, topiramate did not increase abstinence from methamphetamine during weeks 6-12. For secondary outcomes, topiramate reduced weekly median urine methamphetamine levels and observer-rated severity of dependence scores significantly. Subjects with negative urine before randomization (n = 26) had significantly greater abstinence on topiramate versus placebo during study weeks 6-12. Topiramate was safe and well tolerated. CONCLUSIONS: Topiramate does not appear to promote abstinence in methamphetamine users but can reduce the amount taken and reduce relapse rates in those who are already abstinent. |*Methamphetamine[MESH] |Adult[MESH] |Amphetamine-Related Disorders/*rehabilitation[MESH] |Double-Blind Method[MESH] |Excitatory Amino Acid Antagonists/*therapeutic use[MESH] |Female[MESH] |Fructose/*analogs & derivatives/therapeutic use[MESH] |GABA Agents/*therapeutic use[MESH] |Humans[MESH] |Male[MESH] |Medication Adherence[MESH] |Middle Aged[MESH] |Psychometrics[MESH] |Topiramate[MESH] |Treatment Outcome[MESH]Topiramate for the treatment of methamphetamine addiction: a multi-cen(epmc).pdf DeepDyve Pubget Overpricing